Release time：Nov 23, 2020
On November 23, 2020, the antibody drug industrialization project of Jiangsu T-mab, a wholly-owned subsidiary of Mabwell, was launched in Taizhou Pharmaceutical High-tech Zone. The leaders of Taizhou Municipal Government, Chairman Mabwell, Mr. Chunshan Tang, Mabwell President Dr. Datao Liu, Mabwell President Dr. Datao Liu and Jiangsu T-mab Executive Director and GM Dr. Ning Xie and other company leaders attended the ceremony. The construction of this project will greatly enhance the industrialization level of antibody drug R&D in China Medical City.
（Site of the ceremony）
After that, Dr. Ning Xie introduced the advantages of the project: “The antibody drug industrialization project under construction is an upgrade of production capacity following the small-scale commercial projects that have been completed and put into use. The land area is 53,000 square meters and the total construction area is more than 100,000 square meters. After completion, it will have an annual production capacity of 2,700 kg of antibody protein. The project construction is conformed to EU, US and China GMP standards, and international advanced antibodies are used pharmaceutical equipment and facilities. The products are mainly antibody drugs, ADC drugs and recombinant protein products are taken into consideration which can realize global supply. It become an important industrial force in the country."
After that, Dr. Ning Xie introduced the advantages of the project: “The antibody drug industrialization project under construction this time is an upgrade of production capacity following the small-scale commercial projects that have been completed and put into use. The land area is 53,000 square meters, and the total construction area is more than 100,000 square meters. After completion, it will have an annual production capacity of 2,700 kg of antibody protein. The project construction standards are in line with EU, US and China GMP standards, and international advanced antibodies are used Pharmaceutical equipment and facilities, the products are mainly antibody drugs, and ADC drugs and recombinant protein products are taken into consideration which can realize global supply and become an important industrial force in the country."
（Site of the ceremony）
It is believed that the successful start of the Jiangsu T-mab antibody drug industrialization project will inject new impetus into Mabwell's development strategy and production scale upgrade.
